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Sirt6 is a member of the sirtuin family involved in physiological and pathological processes including aging, cancer, obesity,
diabetes, and energy metabolism. This study is aimed at evaluating the relationship between liver SIRT6 gene expression and the
oxidative stress network depending on adiposity levels in Zucker rats, an animal model of metabolic syndrome. We observed
that liver-specific SIRT6 expression is reduced in an in vivo model of spontaneous obesity and metabolic syndrome. We also
observed that SIRT6 expression in the liver is positively associated with SIRT1 and GST-M2 expressions, two proteins involved
in antioxidant protection pathways and inversely related to body weight and plasmatic oxidative status. Interestingly, the SIRT6
expression is upregulated after energy restriction-induced weight loss concomitantly with an improvement in oxidative stress
markers. These results suggest that SIRT6 may be a potential therapeutic target for the treatment of obesity and associated
metabolic disorders, such as liver disease.
1. Introduction
During the last years, numerous evidences suggested the
oxidative stress as a key factor involved in the development
of obesity and its comorbidities [1]. The oxidative stress in
obesity is induced by an excessive generation and accumula-
tion of reactive oxygen species (ROS) in different cellular
structures due to the expansion of the adipose tissue and
inefficiency in the energy metabolism leading to cellular
damage [2, 3]. The metabolic syndrome associated with obe-
sity identifies subjects who have an increase in morbidity and
mortality and is correlated with the development of several
pathologies that affect different organs such as the liver and
the progression from steatosis to nonalcoholic steatohepatitis
and hepatocarcinogenesis in which oxidative stress appears
to be involved [4].
Sirtuins are a family of NAD+-dependent protein deace-
tylases and ADP-ribosyltransferases with an important role
in regulating the life span, aging, and cancer as well as energy
metabolism and obesity and its metabolic associated disor-
ders [5] and have therefore been proposed as a possible target
for future therapies against these diseases.
Seven highly conserved family members of sirtuins have
been identified (Sirt1-Sirt7) in mammals [6]. A number of
studies revealed that Sirt1 has several beneficial effects on
metabolic cell control and enhances the ability of cells to cope
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with oxidative stress [7, 8]. However, relatively little is known
about the other sirtuins Sirt2 to Sirt7 being suggested that
seven sirtuins may have redundant or similar cellular func-
tions with Sirt1 [9]. In this regard, the nucleus-specific Sirt6
level is involved in obesity and diabetes [10, 11]. Aging and
overnutrition lead to decreased Sirt6 level resulting in alter-
ations of glucose and lipid metabolism [10]. Deletion of Sirt6
in mice resulted in lethal hypoglycemia [9, 12, 13]. On the
other hand, overexpression of Sirt6 improves blood lipid pro-
files in animals fed with high-fat diets [12]. Liver expression
of Sirt6 is induced by caloric restriction and suppressed in
diseases associated with lipid accumulation in the liver [12].
Hepatic-specific deletion of sirt6 resulted to triglyceride
accumulation and liver steatosis [14]. In addition, adipose
tissue-specific ablation of Sirt6 resulted in increased blood
glucose, hepatic steatosis, and diet-induced obesity [10, 13].
Sirt6 levels are reduced in the adipose tissue of murine
models of obesity and increased in the adipose tissue of
humans with weight loss [15, 16].
Therefore, the aim of this study was to evaluate the
hepatic gene expression of SIRT6 and its relationship with
the oxidative stress network depending on adiposity levels
in Zucker rats, an animal model of metabolic syndrome.
2. Experimental Procedures
2.1. Animals.Male lean (Fa/fa;n = 10) andobese (fa/fa;n = 10)
rats of the Zucker strain, 8 weeks old purchased from
Charles River Laboratories (Barcelona, Spain), were main-
tained in controlled conditions of temperature, humidity,
and illumination (12 h controlled photoperiod). They were
allowed to acclimatize for 1 week on arrival. All rats had
free access to water and standard laboratory diet (SAFE;
Panlab, Spain), with 5.5% lipid, 23% protein, and 70%
carbohydrate content. Body weight and food and water
intake were measured during the experimental period.
Finally (22 weeks), animals were euthanized and decapitated,
and the livers and blood were obtained, immediately frozen
on dry ice, and kept at −80°C until analysis. All animal exper-
iments and procedures involved in this study were approved
by the Ethical Committee at the University of Santiago de
Compostela, in accordance with the European Union
Normative for the use of experimental animals.
In the experimental weight loss protocol, fatty rats
(n = 30) were randomly divided into three subgroups: an
energy-restriction group (ER; n = 10), an exercise group
(EX; n = 10), and an energy restriction plus exercise group
(EREX; n = 10). These fatty rats were individually housed
for 1 week, and their individual food intake was weighed
and recorded. Then, the rats in the ER and the EREX groups
were fed a diet 30% less in quantity than their individual food
intake during 4 weeks (based on the weight of food).
Animals from the EX and the EREX groups were placed
on a monitored rodent treadmill (Treadmill system 303401-
R-04/C, TSE-Systems, Inc., Chesterfield, MO, USA) for
10min/day and increased progressively in intensity from
10m/min to 20m/min during 1 week for familiarization.
After that, animals were placed on the treadmill for 30min/
day at 20m/min, 7 days per week for 4 weeks.
2.2. Body Composition. Body composition studies were per-
formed every 2 weeks using a nuclear magnetic resonance
imaging (MRI) system (Whole Body Composition Analyser,
EchoMRI, Echo Medical Systems, USA).
2.3. RNA Extraction and Quantitative RT-PCR. Total RNA
extraction from the liver was performed using Trizol (Invi-
trogen) according to the manufacturer’s recommendations.
The RNA (500ng) was retrotranscribed into cDNA using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, USA). The expression of the genes of interest was
studied using TaqMan real-time PCR in Step One Plus
system (Applied Biosystems, USA) using specific primers
and probes obtained from inventoried TaqMan Gene
Expression Assays (Applied Biosystems, USA) for SIRT6,
SIRT1, and GST-M2 genes. All reactions were performed
using the following cycling parameters: 50°C for 2min,
95°C for 10min, followed by 40 cycles of 95°C for 15 s, 60°C
for 1 minute. For data analysis, the RNA level of the gene
of interest was normalized using the β-actin values, accord-
ing to the 2-ΔΔCt method.
2.4. Oxidative Stress Blood Analysis. Plasmatic malondialde-
hyde (MDA) and total antioxidant capacity (TAC) were
evaluated using commercially available colorimetric assay
kits (OXIS International, Portland, OR, USA).
2.5. Statistical Analysis. The normal distribution was
explored with the Kolmogorov-Smirnov test and the
Shapiro-Wilk test. Because oxidative stress markers and gene
expression levels were not normally distributed, the Mann–
Whitney U test was applied to study the differences between
obese and lean rats. The fold change in gene expression was
calculated using the 2-ΔΔCt relative quantitation method
according to the manufacturer’s guidelines (Applied Biosys-
tems, USA) and reporting the data as the geometric mean
(standard error of the mean, SEM). A p value< 0.05 was
considered to be statistically significant, and a p value≤ 0.1
was considered to be a trend for significance. The potential
association between oxidative stress biomarkers and gene
expression levels was evaluated using the Spearman rank
correlation coefficient. Statistical analysis was performed by
SPSS 15.0 software (SPSS Inc., USA) for Windows XP
(Microsoft, USA) and GraphPad Prism 6.01 software
(GraphPad Software Inc., USA).
3. Results
3.1. Characteristics of the Experimental Animal at 22 Weeks
Old. We fed rats a standard diet while monitoring body
weight gain and body composition. At the end of the experi-
ment, the obese rats (fa/fa) showed higher body weight and
consequently higher fat mass (9×) as well as lower free fat
mass than their lean littermates (Fa/fa) (Table 1). In addition,
plasma levels of oxidative stress biomarkers as MDA and
TAC at the end of the experimental period were lower in lean
than in obese phenotype (Table 1).
3.2. Hepatic Gene Expression of SIRT6, SIRT1, and GST-M2.
Obese rats showed a marked decrease in the hepatic gene
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expression of SIRT6 (30%) and SIRT1 (50%). These results in
SIRT6 and SIRT1 gene expressions were also observed in an
animal model of diet-induced obesity (DIO; Supplementary
Figure 1). In addition, the hepatic gene expression of GST-
M2, the antioxidant enzyme glutathione-S-transferase Mu2,
was also reduced (30%) (Figure 1(a)).
Because SIRT1 and GST-M2 are two proteins with
proven involvement in the antioxidant protection path-
way, we performed an association study between SIRT6
expression and SIRT1 and GST-M2 expression in livers
from all rats taken together. Interestingly, the hepatic
SIRT6 mRNA levels were positively associated with the
gene expression of SIRT 1 (r = 0 59; p = 0 007) and
GST-M2 (r = 0 70; p = 0 037) (Figure 1(b)).
3.3. Association of SIRT6 Gene Expression with Body Weight,
MDA, and TAC. In accordance with the involvement of
SIRT6 in the regulation of oxidative stress process [10]
and its association with SIRT1 and GST-M2 expression
levels, we reasoned that the gene expression of SIRT6 at
the hepatic level should be correlated with body weight
as well as with systemic markers of oxidative stress. In
fact, increased hepatic SIRT6 expression was associated
with lower body weight (Figure 2(a)), lower plasma
MDA levels (Figure 2(b)), and lower plasma TAC
(Figure 2(c)).
3.4. Weight Loss, Systemic Oxidative Stress, and Hepatic Gene
Expression. After the 4 weeks of weight loss treatments, the
ER and EREX groups exhibited 26% less body weight
(Figure 3(a)) than the Ad-L control group and similar to
the lean control animals. No differences were observed
between both groups or between the EX and the Ad-L group
in body weight. According to the body weight loss data, the
ER and EREX groups showed a significant reduction in the
circulating levels of MDA and TAC (Figure 3(b)). Interest-
ingly, in the EX group, despite not producing a reduction in
body weight, it showed a reduction in the circulating levels
of MAD and TAC similar to the effects observed for the
EREX group (Figure 3(b)). Then, we investigated the effect
of the weight loss interventions on hepatic gene expression
of sirtuins and GST-M2. According to the body weight loss
data, the ER and EREX groups but not the EX group showed
a significant increase in SIRT6 and SIRT1 gene expressions
(Figure 3(c)). However, the expression of GST-M2 showed
no significant variations after the interventions (Figure 3(c)).
4. Discussion
This work shows that the oxidative stress induced by excess
of adiposity is related to a downregulation of hepatic SIRT6
expression in obese individuals. After weight loss induced
by energy restriction, the hepatic SIRT6 expression increases,
concomitantly with an improvement in oxidative stress
markers. Therefore, these results suggest that the potential
role of SIRT6 in the protection against oxidative stress dam-
age could be a therapeutic target to treat the damage caused
by the association between obesity and oxidative stress.
Sirtuins play an important regulatory role in energy
metabolism and they may be a potential therapeutic target
for obesity and associated pathologies [5]. Among the sirtuin
family members, sirt1 is the most well-studied sirtuin and it
has been implicated in the protection against cellular
oxidative stress, and it plays an important role in metabolic
pathway regulation, specifically acting in adipocytes as an
inhibitor of adipogenesis. Additionally, the expression of
SIRT1 is modulated by energy restriction in association with
improvements in oxidative stress [7]. In this line, SIRT6 was
recently discovered as a relevant player in the predisposition
to age-associated diseases [17]. The activity of SIRT6 is
reduced in obesity and diabetes and its hepatic-specific
ablation increases liver steatosis onset [10]. However, the
study of SIRT6 is still very fresh [10]. In this work, we showed
a downregulation of SIRT6 in the liver of obese rats com-
pared with their lean littermates.
The liver is a key metabolic organ controlling the overall
lipid metabolism in response to hormonal and nutritional
stimuli received and one of the organs most affected by
excessive intake of carbohydrates or fat leading to metabolic
pathologies associated with obesity. Several studies
highlighted that obesity strongly contributes to the transition
of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic
steatohepatitis (NASH) and hepatocellular carcinoma
(HCC) [18, 19]. The absence of SIRT6 increases the expres-
sion of genes responsible for hepatic long-chain fatty acid
uptake and reduced expression of genes for β-oxidation lead-
ing to accumulation of triglycerides and fatty liver disease
and hepatic steatosis [10]. Additionally, the participation of
ROS in liver disease has been suggested [20]. Moreover, it
was observed that genes related to oxidative stress regulation
are overexpressed in early stages of HCC [21]. In this regard,
obesity produces various metabolic alterations that contrib-
ute very actively to the general oxidative balance, creating
the basis for the development of diseases such as diabetes,
hypertension, cardiovascular disease, and cancer, among
others. According to the literature, the major contributors
to systemic oxidative stress in obesity are hyperglycemia,
increased muscle activity to support weight gain, high lipid
levels in different tissues, chronic inflammation, low antioxi-
dant defenses, endothelial ROS production, and hyperlepti-
nemia [1]. Oxidative stress in obesity is a systematic
problem that can be reduced by improving antioxidant
defenses through fat reduction, physical activity or exercise,
Table 1: Characteristics of the experimental animal at 22 weeks old.
Obese
(n = 10)
Lean
(n = 10) p value
Body weight (g) 559± 28 410± 30 <0.001
Fat mass (g) 213± 11 24± 6 <0.001
Free fat mass (g) 261± 49 303± 19 0.021
MDA (μM) 1.75± 0.64 0.61± 0.19 0.001
TAC (mM Trolox) 436± 191 265± 40 0.020
Data are represented as the mean ± standard error of the mean (SEM).
P value shows statistically significant differences compared with the
control-lean group. MDA: malondialdehyde; TAC: total antioxidant capacity.
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dietary restriction, surgical intervention, or antioxidant
therapies which, based on the results showed in this work,
may include SIRT6.
In accordance with a potential association between the
expression of SIRT6 with oxidative stress, we observed a
correlation between SIRT1 and GST-M2, both genes that
codify proteins involved in the protection against oxidative
stress [7, 22], which were also downregulated in the liver of
obese fa/fa rats. These results suggest a dysregulation in the
antioxidant defenses that promote the oxidative stress char-
acteristic of obesity [23] which was confirmed by the high
circulating levels of MDA and TAC.
The connection between oxidative stress, energy restric-
tion, and sirtuin activity has been shown in the literature.
The energy restriction reduces the cellular levels of NADH
by increasing the NAD+/NADH ratio and causing an
increase in Sirt2 activity [24]. As in the case of Sirt2, Sirt6
activity is also influenced by energy restriction. Prolonged
restriction results in increased activity of Sirt6 at the brain,
muscle, white adipose tissue, and liver levels [12, 13]. In addi-
tion, Sirt6 is also a mediator of the effects induced by energy
restriction. SIRT6 suppression decreases life extension acti-
vated by energy restriction, and SIRT6 overexpression
shows reduced body weight, increased metabolism, and
reduced serum levels of insulin, glucose, cholesterol, and
several adipokines [13, 25].
In this sense, the data obtained in this study show that
body weight loss is associated with an increase in hepatic
SIRT6 expression and a reduction in systematic oxidative
stress biomarkers in a similar way to the well-studied SIRT1.
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Figure 1: Liver expression of SIRT6, SIRT1, and GST-M2 genes in lean or obese rats (a). Data are represented as the mean± standard error of
the mean (SEM). Statistically significant differences compared with control-lean counterparts ∗p < 0 05 vs. normal weight group. Association
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Figure 2: Association of SIRT6 gene expression with body weight (a), MDA (b), and TAC (c).
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Figure 3: Effect of 4 weeks of weight loss interventions on body weight (a), serum oxidative stress biomarkers (b), and hepatic gene
expression (c). Data are represented as mean and SEM, n = 6 − 10 animals/group. ∗p < 0 05 vs. the Ad-L group, ∗∗p < 0 01 vs. the Ad-L
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According to the important role of Sirt6 in the liver related to
lipidic and glucose metabolism [10], these effects are
observed in models of caloric restriction; however, physical
exercise does not seem to have any influence on hepatic
SIRT6 expression, although exercise has a potent reducing
effect of oxidative stress at the systemic level. This suggests
that the exercise model produces a decrease in systemic
oxidative stress similar to the energy restriction model but
probably through a different mechanism in which the skeletal
muscle may be involved. All these data suggest that SIRT6
acts similarly to SIRT1 and may play a key role in regulating
energy metabolism and defense against oxidative stress.
In conclusion, the results of the current work evi-
denced that SIRT6 gene expression shows similar pattern
of SIRT1 gene expression, the most-studied sirtuin mem-
ber, in the context of relationship with excess body weight
and the regulation of oxidative stress. It supports the idea
of a prominent role for SIRT6 as a potential therapeutic
target for the treatment of obesity and associated disease,
particularly liver disease.
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